S
incee its discovery, DNA vaccination has proven itself as an effectivee strategy for the induction of T cell immunity (reviewedd in Rcf. I). DNA vaccines have been shown to inducee long-lasting immunity that results in protection from microbiall infections and from tumor outgrowth in animal model systemss (2) (3) (4) . In addition, encouraging results have been obtained withh the induction of parasite-specific T cell immunity in human DNAA vaccination trials (5) . To further increase the efficacy of DNAA vaccines, several approaches have been developed in the past years.. These include the provision of genes encoding cytokines suchh as 1L-I2 and 1L-2, or costimulatory molecules such as B7-I andd B7-2 (6-9). A conceptually different approach for the optimizationn of DNA vaccines is to maximize the generation of T cell epitopess from DNA vaccine-encoded gene products. The dissectionn of the MHC class I Ag processing pathway over the past decadess has denned rules thai determine the efficiency of Ag processing.. Both the proteasomal degradation system and the TAP transportt system have been shown to restrict the repertoire of peptidess that is available for MHC class I binding (10-14) . Importantly,, due to this restriction, the presentation of both viral and in particularr tumor Ag-derived T cell epitopes is often less than maximal,, and inefficient processing has been shown to adversely affect thee magnitude of T cell responses (15) (16) (17) . Early attempts to increasee vaccination efficiency by optimizing epitope generation havee focused on the use of minigene-encoded T cell epitopes. However,, vaccination with mmigenc DNA vaccines did not improvee and may even reduce the efficiency of T cell induction in comparisonn to whole gene vaccines (Ref. 18 and Resulrs and Discussion) . Discussion).
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Thiss research was supported by the Dutch Career Society (NKI W-2036). ?? Address correspondence and reprint requests to l)r Ion N. V! Schumacher. Departmentt of Immunology. The Netherlands Cancer Institute. Plesmanlaan 121. 106ft CXX Amsterdam, The Netherlands. E-mail addiess; tsehumvj nki.nl Inn this study, we dissected the requirements for optimal inductionn of CD8'" T cell immunity by comparison of a panel of epitope-directedd DNA vaccines. Our results indicate that the immunogenicityy of these model Ags is optimal when fused to the carboxyll terminus of a gene of foreign origin. Furthermore, preexistingg T cell immunity to the carrier protein only marginally affectss the efficiency of this strategy. Using this optimized strategy. >95%% of vaccinated mice contain significant numbers of Ag-specificc CD8 * T cells that can be monitored directly ex vivo. Epitopespecificc T cell memory induced by these vaccines is detectable for >33 mo and protects mice from outgrowth of Ag-expressing tumors. .
Materialss and Methods

Animals Animals
C57BL/66 mice, C57BL 10 mice, and MHC' class If-tteficient mice (19) crossedd to the C57BL/6 background were obtained from the experimental animall department of The Netherlands Cancer Institute (Amsterdam. The Netherlands).. Green fluorescent protein (GFP^-transgcnic mice (20) were kindlyy provided by Dr. R. Torensma (Department of Tumor Immunology, Nijmegenn University Medical Center, Nijmegen, The Netherlands) Al! micee were handled in accordance with institutional guidelines.
DNADNA constivcts
DNAA vaccines were generated by the introduction of target genes or gene fragmentss into the vector peDNA.3.1, A truncated form of nucleoprotein (NP)) derived from influenza A/NT60 OS (aa: I. 2. and 328-4^8) , which containss the H-2D h -restricted epitope NP,^ (aa: ASNENMDAM), was usedd for vaccination (NP). The minigene NP3W. was generated with the primerr set NPWW top <5'-GATCCTAAGCCACCATGGGTGTTCAGATC GCTTCCAACGAAAACATGGACGCTATGTAAGC-3')) and NP3M, bottomm (5'-GGCCGCTTACATAGCGTCC'ATGTT7TCGTTGGAAGCGAT CTGAACACCCATGGTGGCTTAG-3')) To ensure ammo-terminal processingg comparable to the parental protein, the four naturally flanking aminoo acid residues of NP,", (aa: GVQI) were included in the minigene. Thee DNA vaccine encoding the fusion protein NP3w,-GFP, including the flankingflanking amino acid residues GVQI. was generated with the primer set NPJN,-GFPP top (5 '-GGGGGATCCTAAGCC' ACCATGGGTGTTCAGAT CGCC rrcc AACGAAAACATGGACGCT ATGGTGAGCA ACK ;GCGAG-3') andd GFP bottom (5'-CCCTTTC]CCKK.'CGCTTACTTGGACA(KTC'GTC CATG-3')) Generation of'gene constructs encoding a carboxyl-termina! fusion of eitherr NP,,,, or the H-2D ,> -restricted epitope L'7,^ from human papilloma virus '' Abbreviations used in this paper: GFP, green fluorescent protein; NP, nucleoprotein: HPV,, human papilloma virus: 1RLS. internal nbosome entry .sue (HPV)166 E7 (aa: RAHYNIVTF) to GFP. together with the NP-derived flanking aminoo acid residues (see above; GFP-NP^ and GFP-E74.,. reflectively), was performedd as previously described (21 J. A DNA \-accine encoding a carboxyltenranall fusion of NPÏ|S6 to the male-specific minor histocompatibility Ag Dby (Dby-NPjéft)) wis generated with the primer set Dby top (5'-GGGAATrCGC CACCATGAGTCAAGTGGCAGCGG-3')) and Dby-NP!("" bottom (5-GTTGA CTCXiTCrfrjr^iCAATCjGTGrrCACiATCGCTTCCAACGA.AAACATGGAC CTCXiTCrfrjr^iCAATCjGTGrrCACiATCGCTTCCAACGA.AAACATGGAC GCTATGTAAGCGCCGCAAAGGG-3'). .
Geness were cloned into the BamHl and NoA sites of the plasmid pcDNA3.1 too generate pcDNA.NP, pcDNA.NP366. pcDNA.GFP-NP366, pcDNA. GFP~E74",, and pcDNA.NP3wrGFP. For the generation of pcDNA.NPw IRES-GFP,, internal ribosome entry site (TRES)-GFP was inserted downstream off the NP(M, minigeae into the cloning sites NoA and SaR. Dby-NP,w, was cionedd into the EcoRl and NoA sites ofpcDNA3.l to generate peDNA.Dby-NP,W).. Sequences were confinned by sequence analysis. All DNA batches weree purified using EndoFree Plasmid kit (Qiagen. ruiden, Germany). Analysiss of DNA purified in this manner revealed endotoxin contents of <0.25 EU/ml. .
ImmunizationsImmunizations and ex vivo analysis of Ag-specific CDS* Tcells
Micee were injected i.m. in the hind leg with 100 /xg of DNA in 50 filHBSS (Lifee Technologies, Paisley, U.K.) three times at 14-day intervals. At day 88 postimmuntzation, ~ 50 jxl of peripheral blood was drawn for analysis of TT cell responses. Erythrocytes were removed by incubation in erylysis bufferr (155 mM NH4C1, 10 mM KHC03, 0.1 mM IÏDTA (pH 7.4)) on ice forr 15 min. Cells were washed twice with PBA (lx PBS. 0.5% BSA and 0.02%% sodium azide) and stained with FITC-or PE-conjugated anti-CD8/3 <BDD PharMingen, San Diego, CA) together with PE-or allophycocyaninconjugatedd NP366 or E749 tetramers (22, 23) andd 7 jig/ml dextran-sulfate in IMDM (Life Technologies) supplemented withh complete medium f 5% heat-inactivated PCS, 100 U.'ml penicillin, 100 u-g/mll streptomycin, and 0.5 X 10" ? M 2-ME) for 3 days at 37°C. LPS blastss were washed twice with serum-tree IMDM (Life Technologies). A totall of 30 X 10 6 cells/ml were incubated with 50 /xg.'ml NP366 peptide (aa: ASNENMDAM)) in serum-free medium for 1 h at room temperature. Peptide-loadedd blasts were irradiated with 30 Gy and subsequently washed twicee with complete medium.
Forr in vitro rcstimulations, spleen cells were isolated from C57BL/10 micee and MHC class Il-deficient mice that had been immunized with the indicatedd DNA vaccine. A total of 5 X 10'' cells were restimuiated with 0.55 X 10 6 NP3W)-peptide loaded LPS blasts for 7 days in complete medium. Att day 3 of culture. 10 CU/ml human rIL-2 was added. Cells were harvested,, purified over a Lynipholyte-M (Cedarlane Laboratories, Hornby, Ontario,, Canada) gradient, and analyzed for Ag-specific CD8 + T cells by floww cytometry, or used for further functional analysis as described below.
intracellularintracellular cytokine staining
AA total of 1 X 10'' spleen cells were cultured for 4 h in complete medium supplementedd with 50 U ml human rIL-2 and 1 uJ/ml breieldin A (Golgistop:: BD PharMingen) in the presence of 0.1 u.g/ml NP366 peptide or E7499 control peptide. Cells were stained with anti-CD8/3-PE, washed twice, andd subsequently intracellular cytokine stains were conducted using a Cytofix/Cytopermm kit (BD PharMingen) according to the manufacturer's protocol.. Intracellular staining was performed with FITC-conjugated anti-IFN-yy (clone XMG 1.2) .
CytotoxicityCytotoxicity analysis
Inn vitro restimuiated spleen cells were prepared as described above and testedd in a chromium release assay. Splenocytes were serially diluted in triplicatee in 96-well Li-bottom tissue culture plates (Costar, Coming, NY). Labeledd target cells were incubated with 10 ^iM NP366 or E7.49 peptide for 200 min at room temperature. A total of 1 X 10' peptide-loaded ceils were addedd to the effector cells. Chromium release was measured in superaatants (25(25 jx\ 
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calculatedd from tlic following formula: 100 x [(cpm experimental releasee -cpm spontaneous release)/(cpm maximum release -cpm spontaneouss release}].
VirusVirus infection anil tumor challenge
Purifiedd influenza A/NT/60/68 virus was kindly provided by Dr. R. Consalvess (National Institute for Medical Research. London, U.K.). Virus was grownn and titrated in the Department of Virology. Erasmus University (Rotterdam,, The Netherlands). Mice were infected intranasals with 25 nemaggluttnatingg units of virus.
Forr tumor challenge experiments, mice were immunized three times i.m. withh a 14-day interval with the indicated DNA vaccine. Induction of Agspecificc T cell immunity was confirmed by MHC tetramer staining of peripherall blood cells by flow cytometry. Thirty-five days after the third vaccination,, mice were challenged s.c. with 2.5 X 10 4 TC-1 cells (24). Everyy 3-4 days after tumor cell inoculation, tumor size was measured in twoo dimensions. Mice were sacrificed when tumors became necrotic or reachedd a diameter of > 15 mm.
Resultss and Discussion
Carboxyl-terminalCarboxyl-terminal fusion of T cell epitopes to GFP enhances inductioninduction of T cell immunity
Wee and others have previously documented that pronounced influenzaa A NP-specific CD8
T T cell responses can be monitored directlyy ex vivo by MHC tetramer technology in influenza A-infectedd mice (22. 25) . To establish the potential of DNA vaccines in thee induction of CD8 4 T cell immunity, we immunized naive mice Lm.. with a DNA vaccine encoding a large fragment of influenza A NP.. Although up to 4% of NP366-specific CD8~* T cells can be detectedd in some mice. T cell immunity induced by this vaccine appearss highly variable, and measurable T cell responses are observedd in only 20% of the vaccinated mice ( Fig. 1, C and D) . It has previouslyy been argued that suboptimal T cell induction may be thee result of inefficient Ag processing. Therefore, to bypass the requirementt for epitope liberation from the parental protein, mice weree vaccinated with a minigene DNA construct encoding NP366 ass a short peptide fragment. Comparison of the vaccination efficiencyy of the minigene DNA vaccine and the NP gene DNA vaccinee reveals a nonsignificant increase in the number of mice with measurablee NP?Wl-specific T cell responses (25 vs 20%) , albeit withh a reduction in the magnitude of T cell immunity (Fig. \C) . Similarly.. Whitton et al. (18) have shown that, despite circumventingg the requirement for Ag processing, the use of minigene DNA iss not superior to immunization with DNA vaccines encoding the parentall protein. These results show that although epitope productionn from minigene DNA vaccines may be maximal. T cell inductionn is not improved, suggesting that other factors contribute to the efficiencyy of T cell priming. For instance, peptides generated from minigenee vaccines may rapidly be degraded by cytosolic proteases, suchh that only a fraction of the Ag is transported to the endoplasmicc reticulum for the formation of MHC class I complexes. Therefore,, we tested whether improved DNA vaccines could be producedd in which the epitope is expressed in the context of a larger proteinn but can be readily produced upon proteasomal degradation. Previously,, it has been shown that correct processing of the carboxyll terminus of Ags can be a limiting step in the generation of MHCC class 1 epitopes (26) (27) (28) . In contrast, amino-terminal trimmingg of epitope precursors can occur in the lumen of the endoplasmicc reticulum either before or after MHC class 1 loading and doess not appear to be a significant limiting factor in MHC class I-restrictedd Ag presentation (29. 30). To render carboxyl-terminal processingg redundant, the minigene NP366 was fused to the carboxyll terminus of GFP. In addition, the four natural flanking aminoo acid residues of NP366 at the amino terminus were included inn the fusion gene to ensure amino-tenninal processing of this epitopee comparable to the parental protein.
Remarkably,, when this fusion gene is used as a DNA vaccine, pronouncedd NP,^-specific CD8 4 T cell responses can be monitoredd directly ex vivo in 3S of 40 (95%) vaccinated mice ( Fig. 1 . AA and C; all mice that harbor >0.3% Ag-speeiiic CD8 H T cells weree scored as positive). Mice vaccinated with the GFP-NP366 fusionn gene display epitope-specifïc T cell immunity of in average off 2.5% of the CD8* T ceil population present in peripheral blood (Fig.. ID) . Vaccination with a carboxyl-terminal fusion of the HPVló-dcrivedd Ag E749 to GFP also induced epitopc-specific T celll immunity in 20 of 20 mice (Fig. 1, C and D) , indicating that thee potency of this strategy is not restricted to the NP3(l6 epitope.
Immunizationn with these fusion gene vaccines induces functional epitope-specifïcc T cell immunity as judged by the ability to producee IFN-y and to kill target cells upon in vitro stimulation (Fig.  2) .. Together, these results show that fusion of a minigene to GFP renderss DNA vaccination highly efficient. The power of this strategyy is emphasized by the fact that epitope-specitic T cell immunity iss not only detected after in vitro restimulation but can be visualizedd directly ex vivo in 97% of the vaccinated mice.
Wee next established whether amino-terminal location of the NP3066 epitope within the fusion protein would result in equally pronouncedd T cell induction. Vaccination with DNA encoding an amino-terminall fusion of NP3fi(5 to GFP also resulted in Ag-specificc T cell responses that could be visualized directly ex vivo (Fig.  3) .. However, both the frequency of successful vaccination and the magnitudee of the vaccination-induced T cell response are clearly reducedd when compared with carboxyl-terminal fusion of NP-Ï66 (p(p < 0.001). indicating that carboxyl-terminal fusion of the epitopee is favored to amino-terminal fusion for efficient induction off T cell immunity.
Too examine whether direct linkage of the T cell epitope to GFP iss required for the increased effectiveness of epitope-directed DNA vaccinationn or whether coadministration of GFP is sufficient, we 
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NPaee e IRES-GFP P FIGUREE 3. Optimal induction of CD8 ' T cell immunity by carboxylterminall fusion of the Ag to GFP. C57BL/10 mice were immunized with aa DNA vaccine encoding a carboxyl-terminal fusion (GFP~NP!(,," n = 13) orr ami no-term ina! fusion of the Ag to GFP (NP366-GFP, n = 10). Alternatively,, mice were vaccinated with a minigene DNA vaccine (NP3Wl, n ~ 8)) or with the dicistronic DNA vaccine encoding NPJM> and GFP as two separatee translation products from a single mRNA (NP",(I-IRES-GFP, n = 8).. Peripheral blood was drawn at day 8 post-third vaccination and analyzedd for NP-,",,-specific CD8' T cells. Each dot represents an individual mouse,, and the average is depicted as a line.
comparedd the GFP-NPiw, vaccine with a DNA construct that expressess the NP16t, peptide and GFP as separate translation products fromm a single dicistronic mRNA (NP366-IRES-GFP). In none of thee eight mice immunized with the NP366-IRF,S-GFP DNA vaccinee an epitope-specific CD8" Tcell response is detectable {Fig. 3, /;; < 0.001). In contrast, the fusion gene GFP-NP-.6() induces an NPP ^-specific CDS^" T cell response in all vaccinated mice in this experimentt (Fig. 3) .
Priorr studies have indicated that protein translation from IRES is slightlyy less efficient compared with translation from conventional startt sites (E. Hooijberg, personal com muni cation). To directly examinee the relative levels of expression in both configurations, the twoo constructs were cotransfected into COS-7 cells and protein levelss were determined by Western blot analysis. This reveals that levelss of GFP are ~3-foid higher for the fusion protein as comparedd with expression from the dicistronic vector (data not shown). Consequently,, the requirement for genetic fusion of the target Ag andd carrier protein may reflect an intrinsic property of the fusion protein,, such as protection from cytosolic proteases, or may be a consequencee of a reduced production of a putative GFP-derived Th epitopee from the dicistronic vector (see next section). Regardless off the underlying mechanism, covalent linkage of the Ag and carrierr protein is clearly preferable when compared with current dicistronicc vector systems.
EfficiencyEfficiency of the GFP carrier protein depends on nonselj recognition recognition
Wee next studied the mechanisms that may underlie the dramatic improvementt of T cell induction upon vaccination with the fusion genee used. GFP may serve as a earner protein that facilitates the entryy of the linked epitope into the Ag processing machinery and/orr prevents epitope degradation by cytosolic proteases. In addition,, GFP may enhance Ag-spccific CD8' T cell immunity by thee provision of T cell help. To dissect whether T cell help is requiredd for the induction of CD8 : T cell responses by DNA vaccination,, we immunized MHC class ll-deficient mice with the GFP-NP3666 fusion gene, in these mice devoid of CD4 T cells no detectablee Ag-specific T cell response is induced, whereas 8 of 10 wild-typee mice were successfully vaccinated (Fig. 4A, p < 0.005) . Inn vitro restimulation of splenocytes from vaccinated MHC' class 11-deficiLMitt mice did not result in the outgrowth of Ag-specific T celts,, whereas splenocyte cultures from wild-type mice contained highh numbers of NP-6(1-specific CD8 ' T cells, mounting up to 4U%% of the CD8 + T cell population (Fig. 45) . These findings indicatee that induction of CDS* T cell immunity by DNA vaccinationn is critically dependent on CD4 4 T cell help, in line with previouss observations by Levy et al. (31) . This CD4 ' T cell dependencyy is a property of the DNA vaccination strategy and not of thee GFP-NP,W] Ag. as shown by the fact that it is also observed for thee DNA vaccine encoding the NP protein (data not shown), and thatt NPiW,-specific T cell induction in mice harboring tumors expressingg the identical fusion gene is independent of CD4~ T cells (21). .
Thee CD4 + T cell help that is required for successful vaccination mayy be induced by a GFP-encoded helper epitope. Alternatively. crypticc open reading frames encoded in the plasinid used may containn MHC class 11-restricted T cell epitopes as previously shownn for an MHC class 1-restricted epitope (32). To establish whetherr T cell recognition of GFP-derived fragments contributes too the induction ofNP 366 -specific CD8 + T cell immunity, we vaccinatedd GFP-transgenic mice that express GFP in all nucleated cellss (20) . In two of five mice no T cell response was detectable, andd in the remaining three animals the T cell response was significantlyy reduced in magnitude as compared with wild-type animals (0.544 vs 3.7%, Fig. 4A,p < 0.05) . Thus, efficient DNA vaccination requiress CD4 + T cell help and depends on nonself recognition of thee vaccine-encoded carrier protein. Collectively, these data suggestt that one important element of the success of the GFP fusion strategyy is the provision of CD4"* T cell help through recognition off a GFP-eneoded CD4 ' T cell epitope.
PreexistingPreexisting T cell immunity to GFP does not affect application ofof fusion gene DNA vaccines
Ourr current data show that carboxyl-terniinal fusion of CD8* T celll epitopes to a foreign carrier protein dramatically increases the efficiencyy of epitope-specific CDS' *' T cell induction by DNA vaccination.. During clinical application, preexisting CD4* and/or CD88 * T cell immunity to the carrier protein may influence the efficiencyy of this vaccination strategy. For instance, tetanus toxin hass been used as a source of CD4" T cell help in human DNA vaccinationn trials (33) but is also included in childhood vaccination programs.. Preexisting CD4" T cell immunity to a carrier protein couldd conceivably promote the efficiency of epitope-directed DNA vaccinationn by providing increased CD4 + T cell help. Conversely, preexistingg CD8 + T cell immunity to the carrier protein could possiblyy reduce the efficiency of DNA vaccination, either by competitionn for or by inactivation of APCs (34-36). Based on the resultss in CD4-deficient and GFP-transgenic mice, GFP appears to containn a Th epitope. To address whether preexisting T cell immunityy to GFP affects the induction of T cell responses to the Ag off interest, mice were first immunized three times with the GFP-NP 3666 vaccine, and 5 wk later with GFP-E7 49 . Equal amounts of E7 49 -specificc CD8 + T cells were detected in pretreated and in nontreatedd mice (Fig. 5A) , indicating that preexisting T ceil immunityy to GFP did not further increase the induction of CD8 + T cells. .
Wee next studied how preexisting CD8 ' T cell immunity to an epitopee contained within the carrier protein influenced the inductionn of the desired epitope-directed T cell immunity. To this purpose,, we vaccinated mice that had undergone an infection with an influenzaa A strain (A/NT/60/68) that contains the NP 366 epitope. Fivee weeks post-influenza A infection mice have developed NP w ,-specificc CD8" T cell memory (Fig. SB) , and 8 days after infectionn the mice contain large populations of NP-j^-specific effectorr T cells (referred to as "activated") (22, 25) . Vaccination of thesee mice was performed with a DNA vaccine that contains the NP 3(l66 epitope at the amino terminus and the HPVi6 E7 4i) epitope att the carboxyl terminus (NP ÏA6 -GFP-E7 49 ). and the CD8 ' T eel! responsee against the E7 4l> epitope was monitored. Although vaccinationn with the amino-terminal fusion of NP 366 is less efficient as comparedd with carboxyl-terminal fusion (see above), the Ag is sufficientlyy liberated from this precursor gene to be well recognizedd by NP^^-specific T cells and can therefore serve well to inducee recall responses (N. Brouwenstijn and T. Schumacher, unpublishedd observations).
Inn mice undergoing an acute influenza A infection, the magnitudee of the E7 49 -specific T cell response is significantly reduced comparedd with naive mice (Fig. 5C , p < 0.01). However, preexistingg T cell memory to the fusion partner only slightly affects the Effect of preexisting T cell immunity to the earner protein onn vaccination eificieney. A, C57BL/IÜ mice immunized three times with GFP-NP3wjj (primed, n = 8) or naive (n -8) mice were vaccinated with GFP-E74l)) that contains the HPV16 E74g-derived epitope fused to GFP. At dayy 8 post-third vaccination, peripheral blood was drawn and analyzed for HPV-speeificc CD8' T ceils. B and C, For the induction of preexisting NP;f)6-specificc T cell immunity, C57BL/10 mice were infected intranasally withh 25 hemaggiutmating units of influenza A/NT/60/68 virus or left untreatedd (naive, n ~ 5). Five weeks or 8 days post-influenza infection (memoryy and activated, respectively; /; = 6), mice were vaccinated with NP.,6(1-GFP-E74"" DNA, which contains both the NP,0U and the E749 epitope. 5, At dayy 0 before the first vaccination, peripheral blood was drawn to determine thee amount of preexisting NP,(1(1-specHïe CD8 * T cells. C, The percentage off HPV-specific CD8 + T cells was determined at day 8 post-third vaccination.. Two of five naive mice vaccinated with the NPW,-GFP-E749 DNA hadd detectable amounts of NP-""rspecific T celts (C. data not shown), whereass three mice had no detectable NP,6(j-specirk immunity, in tine with thee finding that carboxyl-terminal fusion is more efficient than amino-terminall fusion (Fig. 3) . Competition between the E74" peptide and NPI()(, peptidee for MHC class T-restricted presentation does not appear to be a significantt factor, as induction of E74,,-speeific T celt responses in naive micee is comparable for the NPlf,h-GFP-E74l, and GFP-E749 DNA vaccines. magnitudee of T cell immunity compared with nontreated mice. Together,, these data indicate thai, whereas effector type CD8 + T celll immunity to a carrier protein may hinder the induction of epitope-specificc T cell immunity, CD8 + T cell memory to the fusionn partner does not significantly affect T cell induction by DNA vaccination. .
DNADNA vaccination protects against lethal tumor challenge
Previously,, it has been described that, irrespective of the original magnitudee of a CD8 ' T cell response, 90-95% of Ag-specific CDS'** T celis die following pathogen clearance, and the remaining 55 10% of the T cell population enter the memory pool (reviewed inn Refs. 37 and 38) . DNA vaccination results on average in 2.5% off epitope-specifie CD8 ' T cells in the second week after vaccination.. With a reduction of 90%, T cell memory may be expected too drop to undetectable levels in the peripheral blood very rapidly. However.. 37 and 84 days after DNA vaccination. Ag-specific CD8** T cells can stilt be monitored (37 days post-vaccination: 86%% of the original magnitude; 84 days post-vaccination: 36%). Too determine whether the Ag-specific T cell memory induced by thiss optimized vaccination strategy can confer protection from subsequentt tumor challenge, mice vaccinated with GFP-E749 were challengedd with the HPV E6/E7 transformed TC-1 tumor cell line 55 wk after the third vaccination (24). Only three of eight mice that weree vaccinated with a control DNA vaccine GFP-NP",(, were protectedd from tumor challenge (Fig. 64) . In contrast, seven of eightt mice vaccinated with GFP-E749 were protected from tumor growthh and remained tumor-free for >70 days, indicating that epitope-directedd DNA vaccination provides effective epitope-specifiee protection from tumor challenge. Whether the reduced incidencee of tumor outgrowth in mice vaccinated with the control DNAA vaccine as compared with naive mice (Fig. 63 ) is due to nonspecificc immune activation or involves recognition of the crypticc T cell epitope that is shared between the DNA vaccine and the TC-11 cell line (32) remains to be established. In conclusion, these dataa indicate that DNA vaccines encoding T cell epitopes fused to thee carboxyi terminus of a nonself carrier protein not only induce pronounced,, long-lived T cell immunity but also provide long-term protectionn from tumor outgrowth.
Too determine whether efficient induction of epitope-directed T celll responses by carboxyi-terminal fusion to a carrier protein of foreignn origin is a more general principle, we used the murine male-specificc minor histocompatibility Ag Dby as fusion partner. Becausee Dby is located on the Y chromosome, it is foreign to femalee mice but (ubiquitously) expressed in male mice. Vaccinationn of female mice with Dby-NP,66 vaccine resulted in epitopespecifiee T cell responses in six of seven mice ( Fig. 1.4) . and these cellss are functional as determined by IFN-y staining upon in vitro restimulationn (Fig. 1C) . In contrast, only one of eight male mice hadd detectable levels of NP3(,(,-spccific CD8* T cells ex vivol/; < 0.05).. Furthermore, this difference in the magnitude of epitopedirectedd T cell immunity between male and female mice is maintainedd after in vitro restimulation (Fig. IB, p < immunodominantt CD4 ' T cell epitope but no known CD8"* T cell epitopess (39) supports the notion that this nonself recognition servess to provide CD4 ' T cell help. These data are consistent with priorr observations of Rice et al. (40) that indicate that carboxyiterminall fusion of a CD8 * T cell epitope to a tetanus toxin fragmentt containing a CD4 * T cell epitope results in a highly efficient DNAA vaccine.
Inn this study, we have determined live guidelines for the design off epitope-specifie DNA vaccines. 1} Genetic fusion of T cell epitopess to a carrier protein can dramatically improve DNA vaccinationn compared both to epitope minigenes as well as to the parentall protein. Twenty of 20 mice (100%) vaccinated with this typee of DNA vaccine encoding a HPV-derivcd T cell epitope displayedd pronounced T cell immunity directly ex vivo. Likewise. 38 off 40 mice (95%) immunized with an influenza A NP-containing DNAA vaccine were efficiently vaccinated. Furthermore, one of the twoo mice that scored negative in ex vivo MIÏC tetramer analysis wass shown to contain Ag-specific T cells after one round of in vitroo restimulation (1.4% NP,6(S-specific CD8* T cells, Fig. 4) . suggestingg that the screening method used may still underestimate thee percentage of successfully inimuni/ed mice. 2) Fusion of the epitopee to the carboxyl terminus of a carrier protein is superior to iimino-terminall fusion or coexpresston of the two genes. 3) Successfull vaccination is critically dependent on CD4 ' T cell help. 4) Successfull vaccination is significantly reduced when the carrier proteinn is a self-protein. 5 ) Preexisting CDS T cell memory againstt other MHC class 1-restncted epitopes contained within the vaccinee docs not prevent the development of effective immunity againstt the vaccine-encoded target Ag. Collectively, the guidelines definedd in this study should form a useful starting point for the developmentt of epitope-directed DNA vaccines, in particular those encodingg human tumor-associated Ags.
